CSPG4 and melanoma: In our analysis of T-cell responses in the previously described patient model Ma-Mel-86 (10), we have identified two melanoma-reactive CD8+ T-cell clones, 11C/73 (11) and 2C/165, targeting the TAA chondroitin sulfate proteoglycan 4 (CSPG4).